Migraine
Conditions
Brief summary
The study involves approximately 105 adolescent (ages 12-17) subjects to be screened at 4 sites across the US. All subjects enrolled will treat up to 4 MILD migraines over a 6 month period. They will be required to have three office visits during the six months. All subjects will be randomized to either Treximet (85mg Imitrex/500mg Naproxen Sodium) or Placebo (sugar-pill) in four of the five treatment arms with a 3 to 1 ratio. A fifth treatment arm will treat all 4 migraines with active drug, Treximet. The hypothesis is that Treximet will prove to be a safe and effective treatment for this population, that has so few treatment for migraine. And Treximet will be superior over placebo for pain free endpoints at 2 and 24 hours.
Detailed description
There are two primary treatment comparisons for this study: 1) the percentage of subjects' pain free at 2 hours after treatment with TREXIMET versus placebo across attacks, and 2) the percentage of subjects who are sustained pain free at 24 hours after treatment with TREXIMET versus placebo across attacks. The following alternative hypothesis will be tested to see if there is a difference in the proportion of subjects who are pain free at 2 hours with TREXIMET versus placebo at all attacks, OR there is a difference in the proportion of subjects who are sustained pain free at 24 hours with TREXIMET versus placebo at all attacks.
Interventions
DRUGTreximet
85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
DRUGPlacebo
Dummy pill comparator
Sponsors
GlaxoSmithKline
Premiere Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
12 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female subjects between the ages of 12-17. 2. Subject has migraine with or without aura (ICHD-II criteria, 1.2.1 or 1.1). A history of at least 1 but no more than 8 attacks per month on average over the past 6 months prior to screening visit. Attacks should be moderate to severe and last for at least 3 hours. 3. Subject is able to distinguish migraine from other headaches and can determine when a mild headache will become a moderate/severe migraine. 4. Female subjects are eligible for participation provided they are of non-child bearing potential or if started menses; they are on a stable regimen of approved contraception. 5. Subject and subject's parent or legal guardian are able to read and write English. 6. Subject is able to read, comprehend, and complete subject diaries. 7. Subjects' parent or legal guardian is willing and able to provide Informed Consent prior to subject entry into the study. 8. Subject is willing and able to provide Informed Assent prior to entry into the study.
Exclusion criteria
Subjects meeting any of the following criteria must not be enrolled in the study: 1. Subject is \< 74 pounds (33.3kg) and no greater than 260lbs (117.9kg) 2. Subject has greater than or equal to 15 headache days per month in total. 3. Subject has secondary headaches i.e. complex migraine, hemiplegic, or basilar. 4. Subject, in investigators opinion is likely to have unrecognized cardiovascular or cerebrovascular disease. 5. Subject has uncontrolled hypertension at screening or is taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker. 6. Subject has a history of congenital heart disease, cardiac arrhythmias requiring medication, or a history of a clinically significant electrocardiogram abnormality that, in the investigator's opinion, contraindicates participation in the study. 7. Subject has evidence or history of any ischemic vascular diseases including: ischemic heart disease, ischemic abdominal syndromes, peripheral vascular disease, or signs/symptoms consistent with the above. 8. Subject has a evidence or history of central nervous system pathology including stroke and/or transient ischemic attacks (TIAs), epilepsy or structural brain lesions which lower the convulsive threshold, or has been treated with an anti-epileptic drug for seizure control within 5 years prior to screening. 9. Subject has a history of impaired hepatic or renal function that, in the investigator's opinion, contraindicates participation in this study. 10. Subject has a hypersensitivity, allergy, intolerance, or contraindication to the use any triptan, NSAID, or aspirin (including all sumatriptan and naproxen preparations) or has nasal polyps or asthma. 11. Subject has used an ergot medication in the previous three months for migraine prophylaxis or is taking a medication that is not stabilized for at least two months for either chronic or intermittent migraine prophylaxis or other co-morbid condition. 12. Subject has taken or plans to take a monoamine oxidase inhibitor (MAOI) including herbal preparations containing St. Johns Wort (Hypericum perforatum), anytime within the two weeks prior to screening and two weeks past exit of study. 13. Subject has a history of any bleeding disorder or is currently taking any anti-coagulant or any antiplatelet agent. 14. Subject has evidence or history of any gastrointestinal surgery, GI ulceration, or perforation in the past six months, gastrointestinal bleeding in the past year, or evidence or history of inflammatory bowel disease. 15. Subject is pregnant, actively trying to become pregnant, or breast feeding or Subject is not willing to have pregnancy test(s). 16. Subject has evidence of illicit drug or alcohol abuse within the last year or any concurrent psychiatric condition which, in the investigator's opinion, will likely interfere with study conduct and participation in the trial. 17. Subject has participated in any investigational drug trial within the previous 4 weeks or plans to participate in another study at any time during this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With 2-hour Pain Free Active Study Drug | 3 years | All data was collected and measured from self-reported patient diaries |
| Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose | 3 years | All data was collected and measured from self-reported patient diaries |
| Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention | 3 years | All data was collected and measured from self-reported patient diaries |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To Evaluate the Consistency of Response Across Four Migraine Attacks at 1, 2, 4, and 24 Hours After Treatment. Frequency of Rescue Medications Needed and the Consistency of Other Symptom Relief i.e. Nausea, Vomiting, Photophobia, and Phonophobia. | 3 years | Collected from patient reported paper diaries |
Countries
United States
Participant flow
Recruitment details
The study recruitment period started in March 2010 and the last subject was exited March 2013. The 4 sites who recruited all patients, consisted of 2 private practices and 2 children's hospital based site.
Pre-assignment details
104 patients were randomized and dispensed study drug but only 94 of those patients actually treated at least one migraine, so therefore 94 subjects data was used in the analysis.
Participants by arm
| Arm | Count |
|---|---|
| Adolescents Age 12-17 All subjects were adolescent males and females with diagnosis of Migraine and a frequency of 1-8 migraines per month on average | 104 |
| Total | 104 |
Baseline characteristics
| Characteristic | Adolescents Age 12-17 |
|---|---|
| Age, Categorical <=18 years | 104 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants |
| Age, Continuous | 14.8 years |
| Region of Enrollment United States | 104 participants |
| Sex: Female, Male Female | 65 Participants |
| Sex: Female, Male Male | 39 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 2 / 20 | 8 / 17 | 5 / 19 | 8 / 19 | 7 / 19 |
| serious Total, serious adverse events | 1 / 20 | 0 / 17 | 0 / 19 | 0 / 19 | 0 / 19 |
Outcome results
Primary
Number of Participants With 2-hour Pain Free Active Study Drug
All data was collected and measured from self-reported patient diaries
Time frame: 3 years
Population: The number of subjects randomized to treatment was 104, which included 94 subjects who treated at least one migraine with study drug and were included in the safety and efficacy data analysis
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Migraine Attack 1 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 hours post dose for Active Treatmen | 35 Participants |
| Migraine Attack 1 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 Hours Post Dose for Placebo | 2 Participants |
| Migraine Attack 2 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 Hours Post Dose for Placebo | 2 Participants |
| Migraine Attack 2 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 hours post dose for Active Treatmen | 23 Participants |
| Migraine Attack 3 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 hours post dose for Active Treatmen | 21 Participants |
| Migraine Attack 3 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 Hours Post Dose for Placebo | 3 Participants |
| Migraine Attack 4 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 hours post dose for Active Treatmen | 24 Participants |
| Migraine Attack 4 | Number of Participants With 2-hour Pain Free Active Study Drug | Pain Free at 2 Hours Post Dose for Placebo | 6 Participants |
Comparison: Comparison of percentage of participants pain free at 2 hours post-dose (active) to percentage of participants pain free at 2 hours post-dose (placebo)p-value: 0.0038Chi-squared
Primary
Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention
All data was collected and measured from self-reported patient diaries
Time frame: 3 years
Population: 94 subjects treated at least one migraine attack with active drug or placebo were analyzed while only 74 subjects had the potential to take placebo during one of their 4 migraine attacks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Migraine Attack 1 | Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention | 32 percentage of attacks |
| Migraine Attack 2 | Percentage of Migraine Attacks With Pain Free Response at 2 Hours Post-Dose Following Early Intervention | 18 percentage of attacks |
Primary
Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose
All data was collected and measured from self-reported patient diaries
Time frame: 3 years
Population: Patients who treated with study drug and were pain free at 2 hours and then continued to be pain free through 24 hours
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Migraine Attack 1 | Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose | 86 percentage of attacks |
| Migraine Attack 2 | Percentage of Migraine Attacks With Sustained Pain Free Response From 2 to 24 Hours Post-Dose | 78 percentage of attacks |
p-value: 0.1294Chi-squared
Secondary
To Evaluate the Consistency of Response Across Four Migraine Attacks at 1, 2, 4, and 24 Hours After Treatment. Frequency of Rescue Medications Needed and the Consistency of Other Symptom Relief i.e. Nausea, Vomiting, Photophobia, and Phonophobia.
Collected from patient reported paper diaries
Time frame: 3 years
Population: This analysis data was not collected.